Close Menu

More articles about Business News

The $102 million dollar deal would enhance Danaher's imaging and analysis capabilities.

The acquisition "offers Abbott entry into new market segments, such as forensics, microbiology, and public health, which are new and complementary to Abbott’s existing diagnostics businesses," an Abbott official said.

The firm reported no revenues for the quarter, but it anticipates revenues of between $2 million and $4 million in 2010 tied to sales of its microRNA-based tests.

The companies will evaluate the ability of Transgenomic's mitochondrial mutation-detection technology to detect and quantify the mutations for use in a possible diagnostic test.

The agreement gives Takara a non-exclusive license for the use of the technology with instruments in Japan, and for worldwide use in kits, in the field of research applications.

Idaho Technology said that the agreement is in line with its "ongoing program to license its broad and valuable intellectual property portfolio in cooperation with Roche Diagnostics."

Exiqon said that the divestiture is part of an effort to "gain operational and infrastructural efficiencies and to free up human financial resources."

The companies touted the financial benefits of the transaction, but it appears that the establishment of a broad drug-delivery portfolio attractive to prospective big pharma partners was the primary driver of the deal.

The company said that as a result of the planned divestiture, it will seek partners to co-develop and commercialize its miRNA-based diagnostics.

The company has exclusively licensed inventions related to the modulation of miR-146 and miR-155, key mediators of the inflammatory response.

The application, No. 20020165189, is entitled, "Oligoribonucleotides and Ribonucleases for Cleaving RNA," and specifically claims "oligoribonucleotides and oligoribonucleosides … [with] subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase," according to its abstract.

Helicos will use the funds for R&D efforts and general corporate purposes. Its shares tumbled in response to the offering.

Kapa licensed Idaho's IP related to real-time PCR applications.

Life Technologies gains BioTrove's gene expression and genotyping system, which it expects will complement its next-generation sequencing and PCR portfolio.

Qiagen expects the $90 million deal to complement its earlier purchase of DxS.

The company will work with UCLA to develop a variety of applications for the nanoparticles, including gene, protein, and drug delivery vehicles; and diagnostic imaging reagents.

IP Update: Dec 10, 2009


USPTO Publishes One Patent, Ten Patent Applications Related to RNAi

The funds will be used to support marketing efforts for the firm's ColonSentry test.

The firm plans to use the funding to develop oligonucleotide technologies and to add management for the US market.

The deal, valued at more than $3 million, would provide NuSep with BioInquire's ProteoIQ software, which helps customers identify proteins separated by mass spec instruments.


The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.